Category: COVID Therapies
Authorized COVID Antiviral Fails to Cut Hospitalization Risk
MedPageToday – Molnupiravir failed to reduce the risk for hospitalization or death in high-risk COVID-19 outpatients who took the oral antiviral within 5 days of symptoms, a large open-label multicenter trial found. In more than 25,000 participants in the PANORAMIC study, the rate of all-cause hospitalization or death at 28 days was an identical 0.8% […]
Oct 18, 2022
FDA – FDA added important information to the authorized Fact Sheets for Evusheld (tixagevimab co-packaged with cilgavimab) to inform health care providers and individuals receiving Evusheld of the increased risk for developing COVID-19 when exposed to variants of SARS-CoV-2 that are not neutralized by Evusheld. Detailed neutralization data can be found in the revised authorized Fact […]
Oct 4, 2022
Repurposing existing drugs to fight new COVID-19 variants
Michigan State University – MSU researchers are using big data and AI to identify current drugs that could be applied to treat new COVID-19 variants. Finding new ways to treat the novel coronavirus and its ever-changing variants has been a challenge for researchers, especially when the traditional drug development and discovery process can take years. […]
Sep 29, 2022
Remdesivir resistance in transplant recipients with persistent COVID-19
Clinical Infectious Diseases – New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical implications. We describe the first cases of an independently acquired V792I RNA-dependent RNA polymerase mutation developing in renal transplant recipients after remdesivir exposure. Our work underscores the need for augmented efforts to identify concerning mutations and address their clinical implications. Download […]
Sep 28, 2022
SARS-CoV-2 mutation leads to resistance to remdesivir in 2 patients
CIDRAP – A report published yesterday in Clinical Infectious Diseases describes a new SARS-CoV-2 mutation that confers resistance to the COVID-19 antiviral drug remdesivir in two persistently infected kidney transplant recipients treated with immunosuppressive drugs. NYU researchers identified the V792I RNA-dependent 25 RNA polymerase mutation in the transplant patients, who were hospitalized and experienced life-threatening COVID-19 complications […]
Sep 28, 2022